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ABSTRAK 
 
Kajian telah dilakukan untuk menentukan kewujudan keresistanan dalam Candida tropicalis terhadap agen 
antifungus selepas pendedahan kepada antifungus pada kepekatan rendah untuk jangka masa yang lama. Lima 
isolat klinikal Candida tropicalis telah dipilih untuk kajian ini yang sediakala resistan terhadap sama ada 
amphotericin B atau fluconazole. Dua isolat yang sensitif terhadap fluconazole telah didedahkan kepada 0.5 
μg/ml fluconazole dalam kultur kaldu (Sabouraud dekstros) dengan pensubkulturan kerapkali sehingga 14 
minggu. Tiga isolat yang sensitif terhadap amphotericin B telah didedahkan kepada 0.25 – 0.5 μg/ml 
amphotericin B dengan cara yang sama. Pada sela masa berlainan ujian penentuan kepekatan perencatan 
minimum (MIC) dilakukan terhadap isolat tadi dengan kaedah mikropencairan kaldu seperti mana disarankan 
oleh NCCLS (National Committee for Clinical Laboratory Standards). Hasil kajian menunjukkan peningkatan 4-
kali dalam nilai MIC isolat selepas pendedahan kepada antifungus selama 10 minggu dan peningkatan ini 
berterusan sehingga ke akhir kajian. Isolat kawalan yang tidak didedahkan kepada antifungus tidak 
menunjukkan sebarang peningkatan dalam nilai MIC. Profil protein bagi semua isolat diperolehi (melalui teknik 
elektroforesis gel poliakrilamida sodium dodesil sulfat) sebelum dan selepas pendedahan kepada agen 
antifungus. Perubahan dalam profil protein (sama ada wujudnya fraksi baru atau peningkatan kepekatan) 
diperhatikan bagi semua isolat. Sebagai kesimpulan, pengaruhan keresistanan berlaku dalam Candida 
tropicalis yang didedahkan kepada agen antifungus dan kejadian ini dikaitkan dengan perubahan dalam profil 
protein. 
 
ABSTRACT 
 
A study was conducted to determine the development of resistance in Candida tropicalis against antifungal 
agents after long-term exposure to low drug concentrations. Five clinical isolates of Candida tropicalis were 
selected for this study. These isolates were found to have already shown resistance to either amphotericin B or to 
fluconazole. Two isolates that were sensitive to fluconazole were exposed to 0.5 μg/ml of fluconazole in a broth 
culture (Sabouraud dextrose broth) with frequent subculturing for up to 14 weeks. Three isolates that were 
sensitive to amphotericin B were exposed to 0.25 – 0.5 μg/ml of amphotericin B in the same way. At different 
time intervals, the MIC values of the isolates were determined by the broth microdilution  test as proposed by the 
National Committee for Clinical Laboratory Standards (NCCLS). Our results showed a 4-fold increase in the 
MIC values after 10 weeks of exposure to the antifungal agent, which continued to rise until the end of the 
experiment. Control isolates not exposed to antifungal agents showed no increase in their MIC values. Protein 
profiles of all isolates (using sodium dodecyl sulphate polyacrylamide gel electrophoresis) were obtained before 
and after exposure to antifungal agent. A change in the protein profile  (new fractions or increased 
concentration) was observed for all isolates. In conclusion, induction of resistance was observed in Candida 
tropicalis isolates exposed to antifungal agents and this occurrence correlates with a change in the protein 
profile. 
 
INTRODUCTION 
 
Candida sp. infections are the most frequently 
occuring opportunistic fungal infection in the 
immunocompromised patient. The causative species 
are Candida albicans, Candida tropicalis, Candida 
parapsilosis, Candida glabrata, Candida krusei and 
others (Meunier et al. 1992). Treatment of these 
infections is limited to the trazole drug, fluconazole 
and   the   polyene,    amphotericin  B.   Fluconazole,  
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however, is not effective in treating C.krusei and 
C.glabrata infections as these species are innately 
less susceptible to this antifungal agent (Wingard, 
1995).  
The mainstay of therapy for serious, life-
threatening fungal infections is still amphotericin B. 
Fluconazole has been given as prophylaxis, 
especially to AIDS patients, due to their high risk of 
developing fungal infections. Long-term antifungal 
therapy is often necessary when systemic fungal 
infections occur. Studies have shown that long-term 
exposure to and prophylactic use of, antifungal 
agents have led to resistance development in 
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Candida sp. (Vanden Bossche et al. 1994, Millon et 
al. 1994).  
The development of resistance is seen 
primarily in C.albicans and to a lesser extent in  
C.tropicalis and C.parapsilosis. The use of 
fluconazole and long-term, low dose therapy with 
amphotericin B also appears to select for infections 
of less susceptible Candida species such as C.krusei 
and C.glabrata (Rex et al. 1993, Georgopapadakou 
et al. 1996). 
Studies on the mechanisms and development 
of resistance have mainly focused on C.albicans and 
C.glabrata.  In this study, we determine the 
development of resistance in C.tropicalis, in vitro, 
and observe fungal protein profiles for any related 
changes. 
 
METHODOLOGY 
 
Five clinical isolates of Candida tropicalis were 
obtained from the Institute for Medical Research, 
Kuala Lumpur. The MIC values of fluconazole and 
amphotericin B for these isolates were determined 
with either the broth microdilution method (National 
Committee for Clinical Laboratory Standards) or the 
commercially available Etest strip (AB Biodisk, 
Solna, Sweden). Interpretation of the MIC values 
were done using the interpretive breakpoints given 
in the National Committee for Clinical Laboratory 
Standards (NCCLS) document M27 A.  
Isolates that were sensitive to fluconazole 
were exposed to 0.5μg/ml fluconazole and isolates 
that were sensitive to amphotericin B were exposed 
to 0.25-0.5 μg/ml amphotericin B. The concentration 
of the antifungal agent used was based on the MIC 
value for each isolate, i.e. the concentration being 
less than the MIC value.  
The isolates were incubated in 20 ml of 
Sabouraud dextrose broth, containing the antifungal 
agent, at 37oC, with frequent subculturing, as 
outlined in Figure 1. At different time-points 
throughout this period of exposure, the MIC values 
for the isolates were determined with the broth 
microdilution method. The MIC of the control strain 
Candida parapsilosis ATCC 200219, as 
recommended by the NCCLS, was also determined 
each time. A control experiment with the 
C.tropicalis isolates was also carried out in which 
the isolates were subcultured in the same way for the 
same time period, but not exposed to the antifungal 
agent. 
 
 
 
 
C.tropicalis isolate on SDA plates 
 
 
Subcultured in 20 ml SD broth at 37oC for 48 hours 
 
 
Subcultured in 20 ml SD broth at 37oC for 48 hours 
 
 
Subcultured onto SDA plates at 37oC for 24 hours       
 
 
Plates maintained at 4oC for 48 hours 
 
 
Subculture procedure repeated 
 
 
Note:  Both SDA plates and SD broth contained the antifungal agen 
at the specified concentration 
 
 
Figure 1: Method of subculture for each week throughout the experimental period 
 
 
At the end of the exposure period (either 10 or 14 
weeks), crude cytoplasmic protein extract of each 
isolate was obtained, based on the method by 
Manning and Mitchell (1980). Briefly, yeast cells 
from a 50 ml Sabouraud dextrose overnight broth 
culture were pelleted and washed twice in saline. 
The cells were resuspended in distilled water and 0.1 
ml of 10 mM PMSF (phenylmethylsulfonyl fluoride) 
to achieve a final volume of 1 ml. Twice this volume 
of 0.45 mm glass beads (2ml) were added to the cell 
suspension and vortexed at a maximum speed for a 
total of 15-20 minutes to obtain adequate cell lysis. 
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Cells were maintained at 4oC throughout, by placing 
them in ice between short periods of vortexing. The 
suspension was centrifuged to separate cell debris 
from the supernatant which contained cytoplasmic 
proteins. This protein extract was obtained for each 
C.tropicalis isolate before and after exposure to the 
antifungal agent. 
Sodium dodecyl sulphate polyacrylamide gel 
electrophoresis (SDS-PAGE) was carried out with 
12.5% resolving gel and 5 % stacking gel in a 
discontinuous system as described by Laemmli 
(1970) in order to separate the proteins in each 
extract. Broad range protein molecular weight 
marker (Sigma, MO) was run in each gel. Gels were 
stained with Coomasie Blue and visualised to 
identify protein fractions. 
 
RESULTS 
 
The MIC values for the five C.tropicalis 
isolates at the start of the study were as shown in 
Table 1. Also shown in the table are the antifungal 
concentrations to which the isolates were exposed to 
in the study. The MIC values for the isolates during 
the period of drug exposure and at the end of this 
time are shown in Table 2. Also shown are the MIC 
values of the control isolates that were not exposed 
to antifungal agent, but subcultured for the same 
duration.  
 
 
Table 1: MIC value for isolated prior to antifungal exposure 
 
MIC values (μg/ml) Exposure to antifungal agent (μg/ml) C.tropicalis isolate 
Fluconazole Amphotericin B Fluconazole Amphotericin B 
1 1.0 (S) 4.0 (R) 0.5 - 
2 1.0 (S) 2.0 (R) 0.5 - 
3 64 (R) 1.0 (S) - 0.5 
4 128 (R) 1.0 (S) - 0.5 
5 256 (R) 0.38 (S) - 0.25 
C.parapsilosis ATCC 
200219  2.0 (S) 0.5 (S) - - 
   Note: S=sensitive, R=resistant. Isolates 2 and 5 were tested with the Etest strip. The antifungal agent and 
concentration used for each isolate exposure are shown in the two columns on the right. 
 
 
Table 2: MIC value for isolated after exposure and for control following subculture only,  
at different exposure periods 
 
MIC values (μg/ml) after exposure C.tropicalis isolate Exposure 
drug 2 weeks 7 weeks 9 weeks 10 weeks 14 weeks 
1 Fluconazole 4 16 32 32 (I) - 
1 (control) - - - -   2 (S) - 
2 Fluconazole - - -         8 64 (R) 
2 (control) - - - - 1.0 2 (S) 
3 Ampho B 1.0 2 4   4 (R) - 
3 (control) - - - -   2 (R) - 
4 Ampho B 1.0 2 4   4 (R) - 
4 (control) - - - - 1.0 (S) - 
5 Ampho B - - - 1.0 8 (R) 
5 (control) - - - - 0.5 1.0 (S) 
  2 (S) 
(fluconazole) 
C.parapsilosis 
ATCC 200219  - - - -   1.0 (S) 
 (Ampho B) 
- 
Note:  the end of the study period (10 or 14 weeks). Ampho B = amphotericin B, S = sensitive, I = 
intermediate, R = resistant. 
 
 
Analysis of the protein extracts of the isolates 
and controls by SDS-PAGE revealed several 
differences. Isolates which had been exposed to 
either antifungal agent showed increased production 
of a 47 kiloDalton(kD) protein which was visualised 
as a darker, broader band on the gel. Isolate 5 which 
had been exposed to amphotericin B showed new 
protein bands of 74 and 77 kD.  
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DISCUSSION 
 
In all of the isolates exposed to antifungal agent an 
increase in the MIC value was observed, compared 
to the initial value prior to exposure. For isolates 
exposed to fluconazole this increase was seen 
starting from 2 weeks after exposure and for isolates 
exposed to amphotericin B, increase in MIC was 
noted at 7 weeks into the study. The MIC values 
continued to rise for both antifungal agents until the 
end of the study. A slight increase in the MIC values 
for some control isolates was also observed, 
however this increase was much less than the 
increase for the test isolates.  
The concentrations of antifungal agent used 
for exposure of isolates reflects achievable tissue 
concentrations of the drug in patients, although the 
cumulative drug effect could not be evaluated in this 
experiment. Studies on development of resistance 
have not been carried out on C.tropicalis although it 
is the second most common causative agent of 
candidiasis, after C.albicans. Hence, the results 
obtained in this study may be extrapolated to the 
patient situation. Our findings underline the need for 
sufficient treatment doses of antifungal agents, as a 
low dose may present a risk to the patient of 
resistance developing in the infecting Candida sp. 
This may be more pertinent when the species 
involved is already less susceptible to one antifungal 
agent (as was the case in this study). 
 Results from SDS-PAGE indicated an 
increase in the 47 kD protein in isolates exposed to 
antifungals. This protein is known to be a stress 
protein in Candida sp. (Matthews et al. 1988) , thus 
an increase in its production indicates that the 
presence of antifungals is a stressful situation for the 
organism. The new proteins (74 and 77kD) found in 
an isolate exposed to amphotericin B may also be 
other groups of stress proteins. The exact nature and 
identity of these proteins remain to be determined. 
However, these proteins may serve as a marker for 
resistance in Candida sp. Screening of more isolates 
from the different Candida sp. needs to be carried 
out before this can be determined. 
 
CONCLUSION 
 
Prolonged exposure to low doses of fluconazole and 
amphotericin B induces resistance in C.tropicalis in 
vitro. Isolates that were already resistant to one of 
these antifungal agents developed resistance to the 
other agent as well, when exposed to it. A change in 
the protein profile of the isolates exposed to 
antifungal agent was observed. 
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